The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients
Key facts
- Where
- Turku, FinnországSee the site
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Finnország
- Turku University HospitalTurku, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- EU 2025-523965-97-00
- Record updated
- 2025. december 16.
- Original description
1) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the clinical assessment of patients with lymph node metastases in NSCLC 2) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessment of cancer related distant metastasis in patient level in patients with primary NSCLC 3) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessesment of cancer related local lymph metastasis and distant metastasis in patient level in patients with recurrent NSCL.Read full original descriptionShow less
1) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the clinical assessment of patients with lymph node metastases in NSCLC 2) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessment of cancer related distant metastasis in patient level in patients with primary NSCLC 3) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessesment of cancer related local lymph metastasis and distant metastasis in patient level in patients with recurrent NSCL.
Inclusion: Diagnosis: Histologically confirmed adenocarcinoma or squamous cell carcinoma. Study 1: No previous treatment (surgical, radiotherapy or medical treatment) for NSCLC. Study 2: Lobectomy or stereotactical radiotherapy or chemoradiotherapy for NSCLC. Clinical stage: Study 1: Stage I-III, Age: > 18 yo.
Exclusion: Infections: Patient must not have an uncontrolled serious infection - no other malignancies - no known history of sarcoidosis - Study 2: under six months after radiotherapy - Patient is not able to understand purpose of study - Medical conditions prohibiting whole body PET-CT.